- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00885222
Antidepressant Effect of Deep Brain Stimulation in Parkinson's Disease Patients
Antidepressant Effect of Deep Brain Stimulation (DBS) in Parkinson's Disease (PD) Patients: Relationship of Stimulation Parameters to Improvement in the Clinical Features of Depression in PD Patients.
The purpose of this study is:
- To determine, in the context of a prospective clinical trial, whether stimulation parameters in PD patients treated with DBS, are associated with antidepressant effects.
- To determine whether these antidepressant effects are related to or independent of changes in the motor features of PD.
- To establish a computerized database that includes stimulation parameters and clinical parameters in PD patients treated with DBS.
- To develop a computer-assisted decision making protocol for programming of DBS parameters in both depressed and non-depressed PD patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Depressive symptoms of PD patients are major predictors of their prognosis and quality of life. Therefore, successful treatment of depression is crucial in PD patients. Using deep brain stimulation as an antidepressant (or to augment a standard antidepressant) could be a promising new direction. The hypothesis to be tested in the current project is that treatment with deep brain stimulation will improve both the neurological and the psychiatric (depressive) symptoms of PD. It is further hypothesized that the improvement in depressive symptoms will not be a simple consequence of improvement in neurological status. Data from this open label study will form the basis for planning a larger scale controlled trial in depressed PD patients and exploratory studies in patients with major depression who do not have PD.
Today, programming of DBS is based on the neurological evaluation of the motor features of PD. If our hypothesis is proven, i.e. parameter manipulation of DBS affects the mental features of PD, it is crucial to establish a valid database that will enable to study these effects. Moreover, such a detailed database will be the basis for the development of a computer-assisted decision making protocol for programming of DBS. A novel decision making protocol will maximize the benefits of DBS in both depressed and non-depressed PD patients.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Hadassah Medical Organization
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinically definite PD treated / candidates for treatment with DBS (patients with advanced idiopathic PD who are deemed appropriate for DBS surgery).
- Patients will be included in the study irrespective of whether a diagnosis of major depression (mild to moderate but not severe MDD) is fulfilled at baseline. Patients without depression will be monitored in the study for evidence of treatment emergent depression. Patients with depression will be monitored for antidepressant effects of stimulation change.
- Age 40-75 years
- Male or female.
- Competent and willing to give written informed consent.
Exclusion Criteria:
- Significant suicidal risk [Hamilton Depression scale item 3 (suicide) >2].
- Comorbidity with any Psychotic Disorder, Bipolar Disorder, Post Traumatic Stress Disorder (PTSD), Eating Disorder.
- Lifetime history of substance or alcohol dependence or of abuse in the preceding 12 months
- Significant cognitive decline, as measured by Addenbrooke's Cognitive Examination (ACE) and the Frontal Assessment Battery (FAB).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1
PD patient that were treated with STN DBS and developed depression after the surgery (n=5).
|
DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN.
This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD.
The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months.
Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges.
Patients with depression will be monitored for antidepressant effects of stimulation changes.
Patients without depression will be monitored for evidence of treatment emergent depression.
|
ACTIVE_COMPARATOR: 2
PD patients with depression that are candidates for STN DBS (n=5).
|
DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN.
This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD.
The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months.
Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges.
Patients with depression will be monitored for antidepressant effects of stimulation changes.
Patients without depression will be monitored for evidence of treatment emergent depression.
|
ACTIVE_COMPARATOR: 3
PD patients without depression that are candidates for STN DBS (n=10).
|
DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN.
This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD.
The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months.
Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges.
Patients with depression will be monitored for antidepressant effects of stimulation changes.
Patients without depression will be monitored for evidence of treatment emergent depression.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome measure of the study will be the stimulation parameters of patients who fulfill criteria for MDD at the inception of trial and manifest remission (HAM-D21 score <7) after 4 months (or less) of DBS treatment.
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary outcome measures will be the relationship between improvement in mental status (as measured by HAM-21, BDI, CGI, HAM-A, BPRS and PDQ39) and change in PD symptoms (as measured by UPDRS).
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Zvi Israel, MD, Hadassah Medical Organization
- Study Chair: Hagai Bergman, MD, Hadassah Medical Organization
- Study Chair: Bernard Lerer, MD, Hadassah Medical Organization
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mood Disorders
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Depression
- Depressive Disorder
- Parkinson Disease
- Depressive Disorder, Major
Other Study ID Numbers
- Eitan-DBS-PD-MDD-HMO-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Neurocrine BiosciencesVoyager TherapeuticsCompletedBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Parkinson's Disease | Parkinsonian Disorders | Movement Disorders | Neurodegenerative Diseases | Idiopathic Parkinson's Disease | Basal Ganglia DiseaseUnited States
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
AbbVieRecruitingParkinson's Disease (PD)Germany, Denmark, Spain
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
Hubert FernandezRecruitingParkinson's Disease, IdiopathicUnited States
Clinical Trials on DBS parameters setting
-
Emory UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingParkinson DiseaseUnited States
-
University of Alabama at BirminghamNational Institute of Neurological Disorders and Stroke (NINDS)CompletedParkinson's DiseaseUnited States
-
University of FloridaNational Institutes of Health (NIH); National Science Foundation; MedtronicActive, not recruiting
-
Deep Brain Innovations LLCTerminatedParkinson DiseaseUnited States
-
Chinese PLA General HospitalNot yet recruitingCervical DystoniaChina
-
University Medical Center GroningenUnknown
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
University of Campania "Luigi Vanvitelli"Completed
-
Jaimie M. HendersonHarvard Medical School (HMS and HSDM); The Cleveland Clinic; Weill Medical College... and other collaboratorsCompletedTBI (Traumatic Brain Injury)United States
-
University of Southern CaliforniaCompletedParkinson DiseaseUnited States